The commercial value of an agrochemical product is not confined to the invention described in its patent specification. Considerable value may also reside in the scientific and technical information generated during development and regulatory approval.
Registration of an agricultural remedy can require extensive chemistry, toxicology, environmental, residue, efficacy and stability information. The underlying studies involve substantial expenditure and lengthy periods of testing across different conditions. The resulting dossier therefore represents both a regulatory requirement and a significant commercial asset.
The Department of Agriculture’s 2026 Chemistry Data Requirements Guideline illustrates the extent of the information involved. It addresses, among other matters, safety, efficacy, the characterisation of technical material, impurities, storage stability and the assessment of chemical equivalence. Applicants seeking regulatory approval may accordingly be required to submit detailed information concerning both the active ingredient and the formulated product.
South Africa does not provide a fixed statutory period of data exclusivity under Act 36 of 1947 comparable with certain foreign regulatory systems. Protection instead arises through a combination of statutory confidentiality provisions, access-to-information legislation, contractual arrangements and the broader law relating to confidential information.
Section 17 of Act 36 restricts the disclosure of information acquired in the performance of functions under the Act, subject to the exceptions contained in the section. The Promotion of Access to Information Act provides further protection in relation to records containing third-party trade secrets and confidential financial, commercial, scientific or technical information in circumstances contemplated by that legislation.
These protections do not remove the need for businesses to manage regulatory data deliberately from the beginning of the development process.
Ownership should be clearly established wherever field trials, laboratory work, technical reports or specialist analyses are produced by external organisations. Agreements with laboratories, consultants, contract research organisations and other service providers should address ownership of the resulting material, permitted use, confidentiality, retention of information and access to the underlying data.
Internal controls are equally relevant. Sensitive scientific and technical information should be identified appropriately, circulated only to those who require access and managed in a manner consistent with its confidential status. Records of disclosure may become particularly important where employees, consultants or service providers later move into competing businesses.
Patent protection and confidential-information strategy also need to be considered together. Patent law requires sufficient disclosure of an invention in exchange for a statutory period of exclusivity. Other technical information may derive much of its commercial value from remaining confidential. Regulatory requirements may, in turn, oblige the business to disclose particular information to the authorities.
The resulting strategy is therefore seldom confined to a choice between patent protection and secrecy. Different elements of the same development programme may require different forms of protection.
An invention may warrant patent protection. Manufacturing know-how may be better retained confidentially. Regulatory studies may have to be submitted to the authorities but should remain subject to appropriate contractual and statutory safeguards. Decisions of this nature are most effective when taken during development rather than after the dossier has been completed.
For businesses investing substantially in the registration and commercialisation of agricultural remedies, management of regulatory data should form part of the wider IP strategy. The value created in bringing a product to market extends well beyond the patent itself.
KISCH IP assists businesses in aligning patent protection, confidential information, contractual arrangements and regulatory submissions throughout the product-development process
